Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age40+
SponsorAsger Sverrild
About this trial
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in patients with COPD.
Eligibility criteria
Qualifiers
Written informed consent
A diagnosis of COPD (according to GOLD (GOLD 2021 Report))
≥ 10 packyears smoked (current or ex-smokers)
Age 40 years or older
Disqualifiers
Previous medical history or evidence of an uncontrolled intercurrent illness that in the opinion of the investigator may compromise the safety of the subject in the study or interfere with evaluation of the investigational product or reduce the subject's ability to participate in the study. Subjects with well-controlled comorbid disease (eg, hypertension, hyperlipidemia, gastroesophageal reflux disease) on a stable treatment regimen for 15 days prior to Visit 1 are eligible.
Any concomitant respiratory disease that in the opinion of the investigator will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (e.g., cystic fibrosis, pulmonary fibrosis, aspergillosis, active tuberculosis).
Current asthma
Lung volume reduction surgery for COPD
Trial design
Treatments tested in this trial
- Tezepelumab
- Placebo
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Asger Sverrild
Lead sponsor
Bispebjerg Hospital
Sponsor institution
AstraZeneca
Collaborator
University Hospitals, Leicester
Collaborator
Source ClinicalTrials.gov